Key points are not available for this paper at this time.
Precision medicine has sparked a fierce debate about the pros and cons of a more individualized healthcare strategy. Advances in precision medicine have challenged traditional paradigms of healthcare decision-making. Pharmacogenomics is part of precision medicine. Although genetic testing in drug therapy is still a relatively recent development, it is growing rapidly. Pharmacogenetic tests reveal genetic biomarkers that indicate a person’s drug susceptibility. They are increasingly being used to improve medication adherence; however, their utility in older people with polypharmacy remains to be well-studied. Mental illness is a major public health problem at both the individual and societal levels. Despite advances in psychopharmacology and better knowledge of therapeutic principles, there is still a long way to go to incorporate pharmacogenetic and pharmacogenomic research into psychiatry’s clinical practice. Numerous genetic variants have been associated with anti-psychiatric responses and adverse effects of treatment. The aim of this review is to summarise responses to psychotropic drugs in the context of pharmacogenetic polymorphisms.
Sukumaran et al. (Mon,) studied this question.